Biotechnology company Unicycive Therapeutics announced that three posters related to its drug candidates for kidney diseases will be presented at the American Society of Nephrology (ASN) Kidney Week 2024 in late October. The posters focus on the product candidates oxylanthanum carbonate (OLC) and UNI-494.
OLC is a next-generation lanthanum-based phosphate binder utilizing proprietary nanoparticle technology being developed to treat hyperphosphatemia in patients with chronic kidney disease. Unicycive is seeking approval of OLC by the US Food and Drug Administration (FDA) via the 505(b)(2) regulatory pathway.
UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator. It has a novel mechanism of action that restores mitochondrial function and may be beneficial for the treatment of kidney and other diseases. UNI-494 has been granted orphan drug designation by the FDA to prevent delayed graft function in kidney transplant recipients.
The posters being presented include “Intravenous UNI-494 slows the progression or halts/reverses acute kidney injury when administered after ischemia/reperfusion in rats” and “Combination oxylanthanum carbonate and tenapanor lowers urinary phosphate excretion in rat,” both with Satya Medicherla, PhD, as lead author, and “UNI-494 phase I safety, tolerability, and pharmacokinetics,” with Guru Reddy, PhD, as lead author.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.